Zunveyl ® (benzgalantamine) is now available for the treatment of mild ... or moderate renal impairment (CrCl 9-59mL/min). Zunveyl is not recommended for patients with severe hepatic impairment ...

The scientists showed that, right at the onset of mild illness, the body also produces special T cells previously known only from chronic, severe infections and tumors. Even in the case of ...

Credit: Hugel. Letybo, an acetylcholine release inhibitor and a neuromuscular blocking agent, was approved in March 2024 based on data from three phase 3 trials. Letybo should be administered no ...